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The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 virus 
in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological 
test that indicated whether the individual was infected or not would be highly desirable.  
Coagulaopathies are a common accompaniment to COVID-19, especially micro-clots within 
the lungs. We show here that microclots can be detected in the native plasma of COVID-19 
patient, and in particular that such clots are amyloid in nature as judged by a standard 
fluorogenic stain. This provides a rapid and convenient test (P<0.0001), and suggests that the 
early detection and prevention of such clotting could have an important role in therapy. 
 
Introduction 
The standard method for detecting infection with SARS-CoV-2 leading to COVID-19 
disease involves a genotypic (PCR) test for the virus on nasopharyngeal swabs, but it 
is not particularly pleasant and can have poor sensitivity (1-4). What would be 
desirable is a rapid and phenotypic test on the host that indicates the presence, and if 
possible the severity, of the consequences of infection. Presently, the standard 
method for this is based on CT chest scans for pneumonia, which have high sensitivity 
but lower specificity (see (5-7) and below), but this is neither cheap nor universally 
available.   
 
It is widely recognised (8-13) that extensive blood clotting has a major role in the 
pathophysiology of COVID-19 disease severity and progression, yet so can excessive 
bleeding (14, 15). The solution to this apparent paradox lies in the recognition (16) that 
these phases are separated in time, with excessive clotting preceding the later 
bleeding that is mediated by the clotting-induced depletion of fibrinogen and of von 
Willebrand factor (VWF). This first phase is accompanied by partial fibrinolysis of the 
formed clots, and an extent of D-dimer formation that is predictive of clinical outcomes 
(17). These features, together with the accompanying decrease in platelets 
(thrombocytopaenia), leads to the subsequent bleeding. Thus it is suggested that the 
application of suitably monitored levels of anti-clotting agents in the earlier phase 
provides for a much better outcome (10, 16). 
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As well as the extent of clotting, including the life-threatening disseminated 
intravascular coagulation (DIC) (12), a second issue pertains to its nature. Some years 
ago, we discovered that in the presence of microbial cell wall components (18, 19), 
and in a variety of chronic, inflammatory diseases (20-22) (including sepsis (23)), 
blood fibrinogen can clot into an anomalous, amyloid form (24). These forms are easily 
detected by a fluorogenic stain such as thioflavin T, or the so-called Amytracker stains 
(25). In all cases, however, these experiments were performed in vitro using relevant 
plasma, with clotting being induced by the addition of thrombin. This was also the case 
for plasma from COVID-19 patients, but the signals were so massive that they were 
essentially off the scale. However, as we report here, the plasma of COVID-19 patients 
carries a massive load of preformed amyloid clots (with no thrombin being added), and 




Ethical approval for blood collection and analysis of the patients with COVID-19 and 
healthy individuals, was given by the Health Research Ethics Committee (HREC) of 
Stellenbosch University (reference number: 9521). This laboratory study was carried 
out in strict adherence to the International Declaration of Helsinki, South African 
Guidelines for Good Clinical Practice and the South African Medical Research Council 
(SAMRC), Ethical Guidelines for research. Oral consent was obtained from all 




20 COVID-19-positive samples (11 males and 9 females) were obtained and blood 
samples collected before treatment was embarked upon. Blood samples were 
collected by JS. Platelet poor plasma (PPP) prepared and stored at -80°C, until 
fluorescent microscopy analysis.    
 
Healthy samples 
Our healthy sample was 10 age-matched controls (4 males and 6 females), previously 
collected and stored in our plasma repository. They were non-smokers, with CRP 
levels within healthy ranges, and not on any anti-inflammatory medication.    
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Lung CT scans  
Amongst the COVID-19 patient sample 10 patients were admitted, but stabilized and 
blood drawn and sent home for observation. Where patients were clinically deemed 
as moderate or severely ill,  CT scans of the patients were performed to determine the 
severity of the lung pathology.  We divided our sample into mild disease (no CT scan) 
and moderate to severely ill.  The CT scan and severity score (26) confirmed moderate 
to severely ill patients according to the ‘ground glass’ opacities in the lungs.  
 
Fluorescent Microscopy of patient whole blood and platelet poor plasma 
Fluorescent (anomalous) amyloid signals present in PPP from COVID-19 patients and 
healthy age-matched individuals were studied using PPP that was stored at -80°C.  
On the day of analysis, PPP was thawed  and  incubated with thioflavin T (ThT; 5 µM 
final concentration).  Following this, the sample was incubated for 30 min (protected 
from light) at room temperature. PPP smears were then created by transferring a small 
volume (5 µl) of the stained PPP sample to a microscope slide (similar methods were 
followed to create a blood smear). A cover slip was placed over the prepared smear 
and viewed using a Zeiss AxioObserver 7 fluorescent microscope with a Plan-
Apochromat 63x/1.4 Oil DIC M27 objective.  Unstained samples were also prepared 
with both healthy and COVID-19 PPP, to assess any autofluorescence.  Micrograph 
analysis was done using ImageJ (version 2.0.0-rc-34/1.5a). The % area of amyloid 
were calculated using the thresholding method. Statistical analysis was done using 
Graphpad, Prism 8 (version 8.4.3). 
 
Results 
Age-matched COVID-19 (average age 49.9y) and healthy individuals (49.05y), were 
used in this analysis (p= 0.065). Figure 1 shows representative CT scans of four of the 
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Figure 1A to D: Representative CT scans of a COVID-19 patient. Yellow arrows show 
ground glass opacities. 
 
 
Figure 2 to 4 show representative fluorescent micrographs of PPP from healthy and 
COVID-19 individuals.  In healthy PPP smears (Figure 2), very little ThT fluorescent 
signal is visible, while in COVID-19 individuals (Figure 3), abundant amyloid signal is 
noted.  Note that these signals were as received; no thrombin was added to induce 
clotting. Figure 4 shows the additional presence of fibrous or cellular deposits in the 
PPP smears.  From their appearance, some of these deposits seem to have originated 
from endothelial cells.  There have been reports of extensive endotheliopathy in 
COVID-19 patients (27).    Figure 5A and B show box plots of the % area of amyloid 
signal calculated from representative micrographs of each individual.  A nonparametric 
one-way ANOVA test (Kruskal-Wallis test) between all three groups showed a highly 
significant difference (p = <0.0001). However, a Mann-Whitney analysis between the 
mild and the moderate to severe COVID-19 individuals showed no significant 
difference (p = 0.554). Amyloid formation in plasma is therefore present in the early 
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stages of COVID-19, when the patients are sufficiently unwell to visit the hospital and 
in need of stabilization.    
 
Figure 2 A to D):  Representative fluorescent micrographs of platelet poor plasma 
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Figure 3A to H): Representative fluorescent micrographs of platelet poor plasma from 
COVID-19 patients.  
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Figure 5A and B: Amyloid % area in platelet poor plasma smears with mean and SEM 
(p = <0.0001). A) All controls and all COVID-19 patients.  B) All controls vs 10 mild 
and 10 moderate to severely ill patients. 
 
   
Discussion 
Strongly bound up with the coagulopathies accompanying severe COVID-19 disease 
is the presence of hyperferritinaemia (in cases such as the present it is a cell damage 
marker (28)) and a cytokine storm, (29-33) which usually occurs in the later phase of 
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the disease (16). Excess iron has long been known to cause blood to clot into an 
anomalous form (34), later shown to be amyloid in nature (18-24).  These kinds of 
phenomena seem to accompany essentially every kind of inflammatory disease (e.g. 
(35)), but the amyloidogenic coagulopathies are normally assessed following the ex 
vivo addition of thrombin to samples of plasma. 
 
Many clinical features of COVID-19 are unprecedented, and here we demonstrate yet 
another: the presence in platelet poor plasma to which thrombin has not been added 
of amyloid microclots. This kind of phenomenon explains at once the extensive 
microclotting that is such a feature of COVID-19 (8), and adds strongly to the view that 
its prevention via anti-clotting agents should lie at the heart of therapy.    Although 
fluorescence microscopy is a specialized laboratory technique, TEG is a well-known 
point of care technique, which is cheap and reliable.  All told, the relative ease, speed 
(40 minutes including 30 minutes ThT incubation time) and cheapness of the assay 
we describe might be of considerable prognostic utility in assessing the clinical status 
of COVID-19 patients. 
 
Of course this must also be monitored (e.g. via Thromboelastography (36-39)) lest the 
disease enters its later phase in which bleeding rather than clotting is the greater 
danger (16).  An important consideration is that TEG can be used to study the clotting 
parameters of both whole blood and PPP. Whole blood TEG gives information on the 
clotting potential affected by the presence of both platelets and fibrinogen, while PPP 
TEG only presents evidence of the clotting potential of the plasma proteins (36-39). 
 
Point-of-care devices and diagnostics like TEG are also particularly useful to assess 
fibrinolysis.  In COVID-19 patients, Wright and co-workers reported fibrinolysis 
shutdown, confirmed by complete failure of clot lysis at 30 minutes on the TEG (40).   
Thus TEG can therefore predict thromboembolic events in patients with COVID-19 
(40). What we have shown here is that the clotting that is commonly seen in COVID-
19 patients is in an amyloid form; this alone would explain the complete shutdown of 
fibrinolysis and the decreased ability to pass O2 into the blood that is such a feature of 
the disease. Consequently, its prevention must lie at the heart of therapies. 
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Figure 1A to D: Representative CT scans of a COVID-19 patient. Yellow arrows show 
ground glass opacities. 
 
Figure 2 A to D):  Representative fluorescent micrographs of platelet poor plasma 
from healthy individuals. Some signals are very slight, as shown by the arrows in A). 
 
Figure 3A to H): Representative fluorescent micrographs of platelet poor plasma from 
COVID-19 patients.  
 
Figure 4: Fibrous or cellular deposits in the plasma smears of COVID-19 patients. 
 
Figure 5A and B: Amyloid % area in platelet poor plasma smears with mean and SEM 
(p = <0.0001). A) All controls and all COVID-19 patients.  B) All controls vs 10 mild 
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